Effects of the SRC Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Phase I Trial
Journal of Bone and Mineral Research - United States
doi 10.1359/jbmr.090830
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2010
Authors
Publisher
Wiley